Puma Biotechnology (PBYI) Net Margin Steady At 13.6% Challenges Bearish Earnings Narratives

Puma Biotechnology (PBYI) closed FY 2025 with Q4 revenue of US$75.5 million and basic EPS of US$0.27, alongside net income of US$13.4 million that helped deliver trailing twelve month net income of US$31.1 million and basic EPS of US$0.62. Over recent quarters, the company has seen revenue move from US$46.0 million and EPS of US$0.06 in Q1 2025 to US$75.5 million and EPS of US$0.27 in Q4 2025. This positions investors to focus on how steadily improving margins underpin the current earnings story.

See our full analysis for Puma Biotechnology.

With the headline numbers on the table, the next step is to see how this earnings profile lines up against the key bullish and bearish narratives that have built around Puma Biotechnology over the past year.

See what the community is saying about Puma Biotechnology

TTM net margin steady at 13.6%

• Trailing twelve month net income of US$31.1 million on US$228.4 million of revenue translates to a 13.6% net margin, a touch higher than the 13.1% margin a year earlier.
• Consensus narrative flags rising R&D and pricing pressure as potential drags on profitability, yet
  • the current 13.6% margin and profitability over the past five years sit alongside forecasts that earnings could decline about 11.2% per year over the next three years.
  • this combination of positive trailing margin and forecast pressure means you are looking at a business that is currently profitable while analysts see thinner margins ahead.

DCF fair value far above US$7.26

• At a share price of US$7.26 and a trailing P/E of 11.9x, the stock is described as trading well below a DCF fair value of about US$25.45, while still on a richer P/E than the 9.7x peer average.
• Bulls point to this valuation gap and past profit growth, but
  • the same dataset notes earnings grew very strongly over five years yet only 2.8% over the last year, and forecasts now point to multi year earnings declines.
  • that tension between a low price versus DCF and weaker forward earnings expectations is exactly what you would be weighing if you see the 13.6% margin as sustainable.

On this set of numbers, bulls argue the current profitability and large gap to DCF fair value could matter more than the cautious earnings forecasts, while skeptics focus on the projected earnings declines and richer P/E versus close peers. If you want to see how bullish analysts stitch that together into a full story, check out the 🐂 Puma Biotechnology Bull Case

Forecast earnings decline vs 72.5% history

• Analysts in the dataset expect earnings to fall about 11.2% per year over the next three years even though earnings grew 72.5% per year over the past five years and the latest trailing margin is 13.6%.
• Bears highlight this turn in the earnings profile, arguing that
  • continued dependence on a single drug and guidance for higher gross to net adjustments could pressure both the modestly growing trailing revenue base of US$228.4 million and that 13.6% margin.
  • if revenue growth stays weak and margins compress from here, the current 11.9x P/E could prove demanding compared with the 9.7x peer average even if it still looks lower than the 17.8x wider biotech group.

If the risk of earnings shrinking from here is what stands out most to you, it is worth seeing how bears frame that argument against the same set of figures in the 🐻 Puma Biotechnology Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Puma Biotechnology on Simply Wall St. Add the company to your watchlist or portfolio so you’ll be alerted when the story evolves.

With bulls and bears both finding support in the same set of numbers, the real edge comes from how quickly you assess the trade off yourself and weigh the 2 key rewards and 1 important warning sign.

See What Else Is Out There

Puma Biotechnology faces a mix of forecast earnings declines, margin pressure risks and a P/E that already sits above the peer average.

If that combination leaves you wanting stronger earnings support for the price you pay, compare this setup with companies screened as 51 high quality undervalued stocks

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com